Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IVERAZITH: Azithromycin + Ivermectin for Pediculosis
NCT03578679Completed
- Sponsor
- Institut de Recherche pour le Développement
- Start
- Jul 2018
- Primary completion
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of azithromycin and CHILD-IVITAB in pediculosis capitis, sponsored by Institut de Recherche pour le Développement. Primary endpoint: Parasiticidal efficacy: disappearance of head lice at Day 7. Started Jul 2018; status: completed.
02
Drugs
azithromycinCHILD-IVITAB
03
Conditions
pediculosis capitis
Beyond the preview
Go deeper on NCT03578679.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03578679.